1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Neurometrix Inc.

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter.
Shai Gozani

1000 Winter St
Waltham, Massachusetts 02451-1436
Phone: 17818909989


NeuroMetrix to Exhibit Quell Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
Mar 21, 2023 13:00pm

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented. Fibromyalgia is a chronic condition characterized by generalized

NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript
Feb 23, 2023 22:23pm

NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsThomas Higgins - Senior VP, CFO & TreasurerShai Gozani - Founder,…

Source:Seeking Alpha
NeuroMetrix GAAP EPS of -$0.09, revenue of $1.84N
Feb 23, 2023 12:16pm

NeuroMetrix press release (NURO): Q4 GAAP EPS of -$0.09.Revenue of $1.84M (+1.1% Y/Y).Gross profit in Q4 2022 was $1.2 million, a decrease of 1.0% from the fourth quarter of 2021

Source:Seeking Alpha
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
Feb 23, 2023 12:00pm

WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
Feb 16, 2023 19:58pm

WOBURN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on February 23, 2023 to discuss its financial results as well as business developments affecting the Company.

Results from NeuroMetrix Inc. (NURO) show potential
Jan 26, 2023 16:24pm

As of Wednesday, NeuroMetrix Inc.’s (NASDAQ:NURO) stock closed at $2.00, up from $1.91 the previous day. While NeuroMetrix Inc. has overperformed by 4.66%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NURO fell by -56.83%, with highs and lows ranging from $5.89 to $1.33, whereas the […]

Source:US Post News